These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28602711)

  • 21. Evidence-based patient choice: a prostate cancer decision aid in plain language.
    Holmes-Rovner M; Stableford S; Fagerlin A; Wei JT; Dunn RL; Ohene-Frempong J; Kelly-Blake K; Rovner DR
    BMC Med Inform Decis Mak; 2005 Jun; 5():16. PubMed ID: 15963238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma.
    Fujikawa K; Matsui Y; Fukuzawa S; Takeuchi H
    Eur Urol; 2000 Feb; 37(2):218-22. PubMed ID: 10705202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
    Bruchovsky N; Klotz L; Crook J; Goldenberg SL
    Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.
    Moul JW; Zlotta AR
    BJU Int; 2005 Feb; 95(3):285-90. PubMed ID: 15679779
    [No Abstract]   [Full Text] [Related]  

  • 25. Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31.
    Souhami L; Bae K; Pilepich M; Sandler H
    Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1301-6. PubMed ID: 20356687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
    Ulloa EW; Salup R; Patterson SG; Jacobsen PB
    Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PCI Choice: Cardiovascular clinicians' perceptions of shared decision making in stable coronary artery disease.
    Coylewright M; O'Neill ES; Dick S; Grande SW
    Patient Educ Couns; 2017 Jun; 100(6):1136-1143. PubMed ID: 28110953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in major depressive disorder and generalised anxiety disorder symptomatology between prostate cancer patients receiving hormone therapy and those who are not.
    Sharpley CF; Bitsika V; Wootten AC; Christie DR
    Psychooncology; 2014 Dec; 23(12):1350-5. PubMed ID: 24789575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
    van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
    BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy.
    Van Poppel H; Joniau S; Van Cleynenbreugel B; Mottaghy FM; Oyen R
    Prostate Cancer Prostatic Dis; 2009; 12(2):116-23. PubMed ID: 19238169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Navigating healthcare: a qualitative study exploring prostate cancer patients' and doctors' experience of consultations using a decision-support intervention.
    Hacking B; Scott SE; Wallace LM; Shepherd SC; Belkora J
    Psychooncology; 2014 Jun; 23(6):665-71. PubMed ID: 24677394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Early detection of prostate cancer by PSA testing: the results of a qualitative study on barriers caused by physicians in Austria implementing informed decision making].
    Malli G
    Gesundheitswesen; 2013 Jan; 75(1):22-8. PubMed ID: 22836936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical relapse in prostate cancer: is PSA promoting stress and anxiety?
    Slovin S
    MedGenMed; 2002 Aug; 4(3):11. PubMed ID: 12466754
    [No Abstract]   [Full Text] [Related]  

  • 35. Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy: a decision analysis.
    Lester-Coll NH; Goldhaber SZ; Sher DJ; D'Amico AV
    Cancer; 2013 May; 119(10):1808-15. PubMed ID: 23400678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How underlying patient beliefs can affect physician-patient communication about prostate-specific antigen testing.
    Farrell MH; Murphy MA; Schneider CE
    Eff Clin Pract; 2002; 5(3):120-9. PubMed ID: 12088291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.
    Beyer DC; McKeough T; Thomas T
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1299-305. PubMed ID: 15817331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study.
    Dale W; Hemmerich J; Bylow K; Mohile S; Mullaney M; Stadler WM
    J Clin Oncol; 2009 Apr; 27(10):1557-63. PubMed ID: 19255325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early outcomes of active surveillance for localized prostate cancer.
    Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
    BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormone therapy can wait in PSA-only relapse.
    Schmidt C
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25122737
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.